These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25249803)

  • 21. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
    Abe H; Minatoguchi S; Ohashi H; Murata I; Minagawa T; Okuma T; Yokoyama H; Takatsu H; Takaya T; Nagano T; Osumi Y; Kakami M; Tsukamoto T; Tanaka T; Hiei K; Fujiwara H
    Hypertens Res; 2007 Oct; 30(10):929-35. PubMed ID: 18049024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Guidelines for diagnosis and therapy of diabetic nephropathy].
    De Ferrari G;
    G Ital Nefrol; 2003; 20 Suppl 24():S96-108. PubMed ID: 14666506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria.
    Lee GS
    Ann Acad Med Singap; 2005 Jan; 34(1):24-30. PubMed ID: 15726216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
    Casas JP; Chua W; Loukogeorgakis S; Vallance P; Smeeth L; Hingorani AD; MacAllister RJ
    Lancet; 2005 Dec; 366(9502):2026-33. PubMed ID: 16338452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
    Parving HH; Jacobsen P; Tarnow L; Rossing P; Lecerf L; Poirier O; Cambien F
    BMJ; 1996 Sep; 313(7057):591-4. PubMed ID: 8806248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
    Parving HH; Rossing P
    Curr Opin Nephrol Hypertens; 1994 May; 3(3):292-300. PubMed ID: 7922255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
    Thomas MC; Atkins RC
    Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Slowing the progression of kidney disease in patients with diabetes.
    Burgess E
    J Am Soc Hypertens; 2008; 2(4 Suppl):S30-7. PubMed ID: 20409936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes.
    Kim SS; Kim JH; Kim IJ
    Endocrinol Metab (Seoul); 2016 Jun; 31(2):245-53. PubMed ID: 27246284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Gilbert RE; Hammond J; Cooper ME; Campbell DJ; Raffaele J
    J Diabetes Complications; 1995; 9(4):308-14. PubMed ID: 8573754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive agents in patients with diabetes: trade-off between renal and cardiovascular protection.
    Navaneethan SD; Querques M; Bonifati C; Strippoli GF
    Diabetes Educ; 2006; 32(4):596-602. PubMed ID: 16873597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
    Khan NA; Hemmelgarn B; Herman RJ; Rabkin SW; McAlister FA; Bell CM; Touyz RM; Padwal R; Leiter LA; Mahon JL; Hill MD; Larochelle P; Feldman RD; Schiffrin EL; Campbell NR; Arnold MO; Moe G; Campbell TS; Milot A; Stone JA; Jones C; Ogilvie RI; Hamet P; Fodor G; Carruthers G; Burns KD; Ruzicka M; dechamplain J; Pylypchuk G; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Vallée M; Howlett J; Katzmarzyk P; Tobe S; Lewanczuk RZ;
    Can J Cardiol; 2008 Jun; 24(6):465-75. PubMed ID: 18548143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic nephropathy: common questions.
    Thorp ML
    Am Fam Physician; 2005 Jul; 72(1):96-9. PubMed ID: 16035688
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.